Eli Lilly to Acquire AtaiBeckley to Accelerate Breakthrough Treatments for Severe Mental Health Conditions
17 Jul 2026
Eli Lilly will acquire AtaiBeckley for up to $3.8 billion, adding BPL-003 and other psychedelic therapies for treatment-resistant depression.
Read More


